ЭФФЕКТИВНОСТЬ АДЪЮВАНТНОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Авторами представлен литературный обзор о направлениях современной адъювантной терапии рака молочной железы. Применение адъювантной химиотерапии, таргетной и гормонотерапии повышает показатели безрецидивной и общей выживаемости больных раком молочной железы. Данные литературы свидетельствуют о целесообразности совместного назначения химио- и таргетной или химио- и гормонотерапии у больных местно-распространенным раком молочной железы. Авторы считают, что адъювантная терапия является достижением в лечении больных раком молочной железы, ее оптимальное применение значимо повышает показатели общей и безрецидивной выживаемости. Несмотря на имеющиеся стандартные схемы химиотерапии, зарекомендовавшие себя высокой эффективностью, безрецидивностью и стабильными показателями выживаемости, медицина не стоит на месте, и ученые ежегодно пытаются разработать новые химио-таргетные препараты, обладающие меньшей токсичностью, которые в скором времени станут приоритетным направлением в адъювантном лечении.

рак молочной железы, адъювантная химиотерапия, таргетная терапия, сүт безі обыры, адъювантный химиотерапия, мақсатты терапия

1. Белохвостова А. С. Таргетная терапия в лечении HER2-позитивного рака молочной железы /А. С Белохвостова, И. А. Смирнова, А. А. Енилеева //Сиб. онкол. журн. - 2013. - №2 (56). - С. 84-88.

2. Жукова Л. Г. Адъювантная терапия трастузумабом при ранних стадиях рака молочной железы: 12 или 24 месяца (по данным ESMO, Вена, октябрь 2012) /Л. Г. Жукова, М. Р. Личиницер //Фарматека. - 2012. - №18. - С. 69-70.

3. Манихас А. Г. Рак молочной железы. Химиотерапия и таргетная терапия /А. Г. Манихас, В. В. Семиглазов, В. Ф. Семиглазов. -М.: 2012. - 360 с.

4. Abdoli G. Breast cancer diagnosis and mortality by tumor stage and migration background in a nationwide cohort study in Sweden / G. Abdoli, M. Bottai, T. Moradi //Breast. - 2017. -V. 31. - P. 57-65.

5. Alba E. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer /E. Alba, F. Andre, C. L. Arteaga //N. Engl. J. Med. - 2016. - V. 375 (18). - P. 1738-1748.

6. Anampa J. Progress in adjuvant chemotherapy for breast cancer: an overview /J. Anampa, D. Makower, J. A. Sparano //BMC Med. -2015. - V. 13. - P. 195.

7. Azambuja E. Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 -year follow-up of a randomised controlled trial / E. Azambuja, L. Gianni, U. Dafni, R. D. Gelber et al. //Lancet Oncol. - 2011. - V. 12 (3). - P. 236244.

8. Barba M. Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series / M. Barba, A. Crispo, G. D'Aiuto et al. //BMC Cancer. - 2013. - V. 13. - P. 15.

9. Barnett J. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer /J. Barnett, K. Gelmon, C. Lohrisch //Clin. Oncol. -2006. - V. 24. - P. 4888-4894.

10. Blows F. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies /F. Blows, K. E. Driver, M. K. Schmidt //PLoS Med. - 2010. - V. 7 (5): e1000279.

11. Boer K. The cyclin - dependent kinase 4/6 inibitor palbociclibin combination with letrozole versus letrozole alone as first - line treatment of oestrogen receptor - positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): a randomized phase study /K. Boer, I. M. Bondarenko, J. P. Crown //The Lancet Oncology. - 2015. - V. 16. - P. 25-35.

12. Boller E. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer e Results from the prospective German TMK cohort study /E. Boller, T. Fietz, M. Janicke //The Breast. - 2017. - V. 34. - 122e130.

13. Bonetti J. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast Cancer: the internatio /J. Bonetti, J. Bernhard, M. Castiglione-Gertsch //Official journal of the American Society of Clinical Oncology. -2009. - V. 18. - P. 1412-1422.

14. Bonifazi M. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice /M. Bonifazi, M. Franchi //The Breast. - 2014. - V. 23. - P. 573-578.

15. Brewer T. M. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2- defined subtypes / T. M. Brewer, H. Masuda, D. D. Liu //Ann. Oncol. Off J. Eur. Soc. Med. Oncol. - 2014. - V. 25 (2). -P. 384-391.

16. Burstein H. J. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: status report. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials //Lancet. -2005. - V. 381. - P. 805-816.

17. Cameron D. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial /D. Cameron, R. D. Gelber, M. J. Piccart-Gebhart //Lancet. - 2017. - V. 389. - P. 1195-1205.

18. Caroline S. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? /S. Caroline, V. David, T. Scott //Breast Cancer. Res. Treat. - 2014. - V. 147 (3). - P. 617-629.

19. Chavez-MacGregor M. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer /M. Chavez-MacGregor, C. A. Clarke, S. H. Giordano //JAMA Oncol. - 2016. - V. 2. - P. 322-329.

20. Cold S. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG) /S. Cold, M. During, M. Ewertz //British journal of cancer. - 2005. - V. 93. - P. 627-632.

21. Conant L. Predictive factors and patterns of recurrence in patients with triple negative breast cancer /L. Conant, L. Steward, F. Gao // Ann. Surg. Oncol. - 2014. - V. 21 (7). - P. 21652171.

22. DeSantis C. E. Cancer treatment and survivorship statistics, 2014 /C. E. DeSantis, C. C. Lin, J. L. Kramer //CA Cancer J. Clin. - 2014. - V. 64. - P. 252-271.

23. Dikshit R. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 /R. Dikshit, S. Eser, J. Ferlay //Int. J. Cancer. - 2015. - №36 (5). - Р. 359-386.

24. Du X. L. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer /X. L. Du, L. Franzini, C. C. Liu //Med. Oncol. - 2013. - V. 30. - P. 419.

25. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials //Lancet. - 2005. - V. 365. - P. 1687-1717.

26. Fan L. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent /K. D. Yu, L. X. Qiu, H. Ling //Oncotarget. - 2017. - V. 8. - P. 4654946556.

27. Ho M. Y.Presentation and management of docetaxel-related adverse effects in patients with breast cancer /M. Y. Ho, J. R. Mackey // Cancer Manag. Res. - 2014. - V. 6. - 253e9.

28. Jemal A. Cancer statistics, 2018 /A. Jemal, K. D. Miller, R. L. Siegel //CA Cancer J. Clin. - 2018. - V. 68 (1). - P. 7-30.

29. Karaki K. Significant association between low baseline neutrophil to lymphocyte ratio and improved progression free survival of patients with locally advanced or metastatic breast cancer treated with eribulin but not with nab paclitaxel /K. Karaki, A. Bun, Y. Fujimoto // Clinical Breast Cancer. - 2018. - V. 18. - P. 400409.

30. Konig J. Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients /J. Konig, L. Schwentner, A. Wockel //BMC Cancer. - 2013. - V. 13 (1). - P. 487.

31. Visvanathan К. Tao Long term side effects of adjuvant chemotherapy in patients with early breast cancer /К. Visvanathan, J. Jessica // The Breast. - 2015. - V. 24. - P. 149-153.

32. Sandoval A. C. Her2-Positive Breast /A. C. Sandoval, R. Mahtani, M. Jahanzeb //FACP. Cancer. - 2019. - V. 34. - P. 107-118.